American College of Cardiology (ACC)

The American College of Cardiology (ACC) is the primary U.S. medical society representing the interests of all cardiology subspecialities. The ACC is very active in setting guidelines for cardiac care, lobbying for supportive government policy and reimbursements, clinician education, managing several key cardiovascular registries and advocating for the transformation of cardiovascular care to improve heart health.

A closer look at GE HealthCare's new lower-cost cardiac CT scanner
As cardiac CT continues to get used more and more, GE HealthCare has launched a new scanner designed to meet the needs of both outpatient imaging centers and larger hospitals.
Cardiologists using less contrast in the cath lab—but there is room to improve
Researchers emphasized that minimizing procedural contrast use is an effective way to reduce the risk of post-PCI acute kidney injury.
Cardiologists make history, use new robotic imaging system for first time
Researchers believe a new robotic TEE system could improve the long-term health of interventional echocardiographers in addition to several other key benefits.
Cardiology employment models undergoing a dramatic shift
Gerald G. Blackwell, MD, MBA, MedAxiom's president and CEO, examined how different cardiology employment models look today compared to even a decade ago.
Cardiology groups among the many voices asking Congress not to cut Medicaid
More than 40 U.S. healthcare organizations are urging Congress not to make sweeping Medicaid cuts that could result in approximately 7.6 million Americans losing health insurance.

FDA clears new device for enabling access to the heart’s surface without an exposed needle

CardioVia's ViaOne technology includes a blunt-tip needle that remains concealed to help interventional cardiologists and electrophysiologists treat cardiac arrhythmias with a reduced risk of perforation or any other complications.

Richard Kovacs, MD, MACC, chief medical officer, American College of Cardiology (ACC), former ACC president, and professor of clinical medicine, Indiana University School of Medicine, explains the most important late-breaking cardiology pharmacology trials at the ACC 2025 meeting. #ACC25 #ACC2025

Late-breaking cardiovascular drug trials took center stage at ACC.25

Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.

Deaths after TAVR are on the rise: Is the pandemic to blame or should cardiologists be concerned?

COVID-19 may help explain the increased rates of cardiac and noncardiac mortality among TAVR patients, but there are several other factors to consider as well. Researchers explored nearly 11 years of STS/ACC registry data to learn more.

A simple way to ensure more heart patients with severe AS receive the care they need

Sending helpful alerts through email and the electronic health record can make a significant impact on patient care, according to new data presented at ACC.25 and published in Circulation.

Patients requiring a permanent pacemaker after TAVR face higher long-term risk of death

As TAVR continues to grow in popularity, researchers noted, it becomes more and more important to know how different complications impact long-term outcomes.

Cardiologist begins term as ACC president with an eye on workforce issues, health equity and more

Christopher M. Kramer, MD, is a longtime cardiologist and cardiac imaging specialist. His one-year term as the head of the American College of Cardiology officially began at the end of ACC.25 in Chicago.

Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, and a clinical professor of medicine at Wake Forest University School of Medicine, offers what he saw as the main takeaway messages in the ACC 2025 late breaking trials.

Key takeaways from ACC.25: Advances in cardiovascular science

Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.

Philippe Généreux, MD, presenting late-breaking clinical research on TAVR at ACC.25

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS

Two separate studies at ACC.25 explored data from the EARLY TAVR trial. One analysis included stroke findings that surprised researchers.

American College of Cardiology (ACC)

A closer look at GE HealthCare's new lower-cost cardiac CT scanner

Cardiologists using less contrast in the cath lab—but there is room to improve

Cardiologists make history, use new robotic imaging system for first time

Cardiology employment models undergoing a dramatic shift

Cardiology groups among the many voices asking Congress not to cut Medicaid